- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05939219
Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine
Clinical Study on the Consistency of 15-valent Pneumococcal Conjugate Vaccine in Three Batches of 3-month-old Population and the Immunogenicity and Safety of Vaccination in 7-5-year-old Population
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: 15-valent pneumococcal conjugate vaccine 202210001
- Biological: 15-valent pneumococcal conjugate vaccineY202210002
- Biological: 15-valent pneumococcal conjugate vaccineY202210003
- Biological: 15-valent pneumococcal conjugate vaccineY202210004
- Biological: 13 valent pneumococcal polysaccharide conjugate vaccine
Detailed Description
The purpose of this experiment
- evaluate the consistency of clinical immune efficacy of three batches of commercially produced 15-valent pneumococcal conjugate vaccines.
- Compare the immunogenicity of commercial scale produced 15-valent pneumococcal conjugate vaccines in the 3-month-old population with the immunogenicity (non inferiority) of pilot scale produced 15-valent pneumococcal conjugate vaccines, that is, a clinical bridging study between commercial scale vaccines and Phase III clinical trial vaccines.
- Evaluate the immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine in the 7-5-year-old population after vaccination.
The commercial three batches and pilot scale batches were designed using a randomized, double-blind, parallel controlled trial of different batches of vaccines. The commercial three batches adopt equivalence design, and the immunogenicity results of the three batches are merged on the basis of equivalence, and compared with the immunogenicity of the pilot scale batch for non-inferiority.
Compare the immunogenicity data of the 7-5-year-old population experimental group with the immunogenicity results of the 3-month-old group (after merging three commercial batches on an equivalent basis) at the basic immune stage for non-inferiority.
At the same time, a positive control was established in the 7-month-5-year-old population, and a randomized, blind design was used to compare the immunogenicity of the experimental group and the control group in this age group.
The study population consists of a total of 2346 people, including 1104 people at the age of 3 months, divided into four groups with 276 people in each group. They were assigned to batch 1, batch 2, batch 3, and the pilot scale module at a ratio of 1:1:1:1. There are a total of 1242 people aged 7 months to 5 years old, divided into three age groups: 7-11 months old, 12-23 months old, and 2-5 years old, with 414 people in each age group. Three age groups of participants were randomly assigned to the experimental group or control group in a 2:1 ratio. The experimental group received a 15-valent pneumococcal conjugate vaccine (batch 3), while the control group received a 13-valent pneumococcal polysaccharide conjugate vaccine produced by Yuxi Watson Biotechnology Co., Ltd. Among them:
- 3 months old: Basic immunization according to the 0, 1, and 2 month program (window period:+10 days); Strengthen immunization with 1 dose at the age of 12-15 months.
- 7-11 months of age: basic immunization with a 0 to 2-month program (window period:+10 days); After 12 months of age, strengthen the vaccination with 1 dose (3rd dose), with a minimum interval of 2 months between the 2nd dose.
- 12-23 months old: Immunize with 2 doses of 0 and 2 month program. The interval between two doses of vaccination should be at least 2 months (window period:+10 days).
- 2-5 years old: receive 1 dose.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wenjian Fang, master
- Phone Number: 18611630252
- Email: fangwenjian@zhifeishengwu.com
Study Locations
-
-
Hebei
-
Shijiangzhuang, Hebei, China, 050021
- Recruiting
- Hebei Provincial Center for Disease Control and Prevention
-
Contact:
- Zhao Gao, Master
- Phone Number: 17796915780
- Email: gaozhao123000@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy infants and children aged 3 months, 7 months, and 5 years old;
- Infants under 1 year old should be born at full term (37 to 42 weeks of pregnancy) and have a birth weight within the range of (2500g ≤ body weight ≤ 4500g);
- After informed consent, the Legal guardian voluntarily signs the informed consent form and can comply with the requirements of the clinical research scheme;
- The subject has no history of receiving other live attenuated vaccines within ≤ 14 days, and no history of receiving other non live vaccines within ≤ 7 days;
- Underarm temperature ≤ 37.0 ℃.
Exclusion Criteria:
- Previously received commercially available or experimental pneumococcal vaccines;
- Have a history of invasive disease caused by Streptococcus pneumoniae that has been confirmed by culture in the past;
- Have a history of severe allergies to vaccines or medication;
- Have a history of Nervous system disease such as convulsion, epilepsy, nervous system tumor, craniocerebral trauma, psychiatric history or family history;
- Babies born under the age of 1 year with severe abnormal birth process (such as instrumental delivery) or a history of asphyxia or neurological organ damage;
- Patients with pathological jaundice confirmed by current diagnosis;
- A history of clearly diagnosed thrombocytopenia or other coagulation disorders may lead to contraindications for injection;
- Immunoglobulin or any blood products (except hepatitis B immunoglobulin) were given within 3 months before enrollment;
- Known or suspected to have immunological function defects, and received long-term Immunosuppressive drug treatment (radiotherapy, chemotherapy, Corticosteroid, antimetabolics, cytotoxic drugs), HIV infection or HIV infected parents within six months before vaccination;
- Having severe congenital malformations, severe malnutrition, developmental disorders, or genetic defects (such as broad bean disease);
- Currently suffering from serious chronic disease, infectious disease, active infection, liver disease, kidney disease, cardiovascular disease, and malignant tumor;
- Absence of spleen or deficiency of spleen function caused by any circumstances;
- Systemic rash, skin ringworm, skin suppuration or blisters;
- Participating in other clinical trials;
- Any situation that the researcher believes may affect the evaluation of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3-month-old group
Randomly inoculate 4 batches of 15-valent pneumococcal conjugate vaccine. Immunization program and dosage: Basic immunization at 0, 1, and 2 months, booster immunization at 12-15 months of age, a total of 4 doses administered. Dosage form: water injection type |
Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Experimental: 7-11 month old experimental group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered. Dosage form: water injection type |
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Active Comparator: 7-11 month old control group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered. Dosage form: water injection type |
Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Experimental: 12-23 months old experimental group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered. Dosage form: water injection type |
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Active Comparator: 12-23 months old control group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered. Dosage form: water injection type |
Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Experimental: 2-5 year old experimental group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: 1 dose administered. Dosage form: water injection type |
Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered.
7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
Active Comparator: 2-5 year old control group
The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: 1 dose administered. Dosage form: water injection type |
Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered.
12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered.
2-5 year old group: 1 dose administered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean concentration of vaccine Serotype specific pneumococcal IgG antibody
Time Frame: 30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old
|
Immunogenicity evaluation
|
30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old
|
Vaccine Serotype specific pneumococcal IgG antibody concentration ≥ 0.35 μg/ml of proportion of subjects
Time Frame: 30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old
|
Immunogenicity evaluation
|
30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old
|
Collaborators and Investigators
Investigators
- Study Chair: Lin Du, master, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202204025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on 15-valent pneumococcal conjugate vaccine 202210001
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNot yet recruiting
-
VA Sierra Nevada Health Care SystemMerck Sharp & Dohme LLCNot yet recruitingImmunosuppression | Pneumococcal Vaccines
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNational Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaboratorsUnknownPneumonia, PneumococcalChina
-
French National Agency for Research on AIDS and...Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccineKorea, Republic of
-
The Hospital for Sick ChildrenCompletedImmunosuppression | Organ TransplantCanada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
PfizerCompletedPneumococcal DiseaseSpain, Poland, Hungary
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalSpain
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted